Summary
Global Markets Direct’s, ‘Seizures - Pipeline Review, H2 2016’, provides an overview of the Seizures pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Seizures
- The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects
- The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seizures
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seizures
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adamas Pharmaceuticals, Inc.
Advicenne
Alexza Pharmaceuticals, Inc.
Biscayne Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc.
Eisai Co., Ltd.
GW Pharmaceuticals Plc
INSYS Therapeutics, Inc.
Lotus Pharmaceutical Co., Ltd.
Marinus Pharmaceutica
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Seizures Overview 8
Therapeutics Development 9
Pipeline Products for Seizures - Overview 9
Pipeline Products for Seizures - Comparative Analysis 10
Seizures - Therapeutics under Development by Companies 11
Seizures - Therapeutics under Investigation by Universities/Institutes 14
Seizures - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Seizures - Products under Development by Companies 19
Seizures - Products under Investigation by Universities/Institutes 23
Seizures - Companies Involved in Therapeutics Development 24
Adamas Pharmaceuticals, Inc. 24
Advicenne 25
Alexza Pharmaceuticals, Inc. 26
Biscayne Pharmaceuticals, Inc. 27
Catalyst Pharmaceuticals, Inc. 28
Eisai Co., Ltd. 29
GW Pharmaceuticals Plc 30
INSYS Therapeutics, Inc. 31
Lotus Pharmaceutical Co., Ltd. 32
Marinus Pharmaceuticals, Inc. 33
Neurelis, Inc. 34
Novartis AG 35
OPKO Health, Inc. 36
Pfizer Inc. 37
PTC Therapeutics, Inc. 38
Sage Therapeutics, Inc. 39
SciFluor Life Sciences, LLC 40
Shire Plc 41
SK Biopharmaceuticals Co., Ltd. 42
Suda Ltd 43
Turing Pharmaceuticals AG 44
UCB S.A. 45
Ultragenyx Pharmaceutical Inc. 46
Upsher-Smith Laboratories, Inc. 47
Xenon Pharmaceuticals Inc. 48
XERIS Pharmaceuticals, Inc. 49
Zogenix, Inc. 50
Zynerba Pharmaceuticals, Inc. 51
Seizures - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 57
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
ADS-4101 - Drug Profile 65
ADV-6208 - Drug Profile 66
ADV-6770 - Drug Profile 67
alprazolam - Drug Profile 68
AMPX-0079 - Drug Profile 70
ataluren - Drug Profile 71
BIS-001 - Drug Profile 79
brivaracetam - Drug Profile 80
cannabidiol - Drug Profile 84
cannabidiol - Drug Profile 90
CCG-63802 - Drug Profile 92
CHEC-9 - Drug Profile 93
clobazam - Drug Profile 94
CNSA-004 - Drug Profile 95
CPP-115 - Drug Profile 96
CUR-1916 - Drug Profile 100
diazepam - Drug Profile 101
diazepam - Drug Profile 103
everolimus - Drug Profile 104
fenfluramine hydrochloride - Drug Profile 115
fosphenytoin sodium - Drug Profile 118
ganaxolone - Drug Profile 119
lacosamide - Drug Profile 124
levetiracetam - Drug Profile 133
levetiracetam ER - Drug Profile 136
lorazepam - Drug Profile 137
LSPGR-1 - Drug Profile 138
magnesium valproate hydrate - Drug Profile 139
MB-003 - Drug Profile 140
midazolam hydrochloride - Drug Profile 141
midazolam hydrochloride - Drug Profile 144
midazolam hydrochloride - Drug Profile 145
midazolam hydrochloride - Drug Profile 146
Oligonucleotide for Dravet Syndrome - Drug Profile 147
perampanel - Drug Profile 148
pregabalin - Drug Profile 155
SAGE-217 - Drug Profile 159
SAGE-689 - Drug Profile 161
selurampanel - Drug Profile 162
sepranolone - Drug Profile 163
SF-0034 - Drug Profile 170
Small Molecule for Stroke and Epilepsy - Drug Profile 172
Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 173
Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 174
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 175
Small Molecules for Seizure Disorders - Drug Profile 176
Small Molecules for Seizures - Drug Profile 177
TG-4155 - Drug Profile 178
TRP-001 - Drug Profile 179
TUR-004 - Drug Profile 180
TUR-005 - Drug Profile 181
UX-007 - Drug Profile 182
YKP-3089 - Drug Profile 187
ZYN-002 - Drug Profile 189
Seizures - Dormant Projects 192
Seizures - Discontinued Products 195
Seizures - Product Development Milestones 196
Featured News & Press Releases 196
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 209
Disclaimer 210
List of Tables
Number of Products under Development for Seizures, H2 2016 13
Number of Products under Development for Seizures - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Comparative Analysis by Unknown Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Development by Companies, H2 2016 (Contd..3) 26
Products under Investigation by Universities/Institutes, H2 2016 27
Seizures - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 28
Seizures - Pipeline by Advicenne, H2 2016 29
Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016 30
Seizures - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 31
Seizures - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 32
Seizures - Pipeline by Eisai Co., Ltd., H2 2016 33
Seizures - Pipeline by GW Pharmaceuticals Plc, H2 2016 34
Seizures - Pipeline by INSYS Therapeutics, Inc., H2 2016 35
Seizures - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 36
Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016 37
Seizures - Pipeline by Neurelis, Inc., H2 2016 38
Seizures - Pipeline by Novartis AG, H2 2016 39
Seizures - Pipeline by OPKO Health, Inc., H2 2016 40
Seizures - Pipeline by Pfizer Inc., H2 2016 41
Seizures - Pipeline by PTC Therapeutics, Inc., H2 2016 42
Seizures - Pipeline by Sage Therapeutics, Inc., H2 2016 43
Seizures - Pipeline by SciFluor Life Sciences, LLC, H2 2016 44
Seizures - Pipeline by Shire Plc, H2 2016 45
Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 46
Seizures - Pipeline by Suda Ltd, H2 2016 47
Seizures - Pipeline by Turing Pharmaceuticals AG , H2 2016 48
Seizures - Pipeline by UCB S.A., H2 2016 49
Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016 50
Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016 51
Seizures - Pipeline by Xenon Pharmaceuticals Inc., H2 2016 52
Seizures - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016 53
Seizures - Pipeline by Zogenix, Inc., H2 2016 54
Seizures - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 55
Assessment by Monotherapy Products, H2 2016 56
Number of Products by Stage and Target, H2 2016 58
Number of Products by Stage and Mechanism of Action, H2 2016 62
Number of Products by Stage and Route of Administration, H2 2016 66
Number of Products by Stage and Molecule Type, H2 2016 68
Seizures - Dormant Projects, H2 2016 196
Seizures - Dormant Projects (Contd..1), H2 2016 197
Seizures - Dormant Projects (Contd..2), H2 2016 198
Seizures - Discontinued Products, H2 2016 199
List of Figures
Number of Products under Development for Seizures, H2 2016 13
Number of Products under Development for Seizures - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Products, H2 2016 21
Assessment by Monotherapy Products, H2 2016 56
Number of Products by Top 10 Targets, H2 2016 57
Number of Products by Stage and Top 10 Targets, H2 2016 57
Number of Products by Top 10 Mechanism of Actions, H2 2016 61
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 61
Number of Products by Top 10 Routes of Administration, H2 2016 65
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 65
Number of Products by Molecule Types, H2 2016 67
Number of Products by Stage and Molecule Types, H2 2016 67
